THERIO careers

Series B $1.7M raise to fund final FDA-mandated re-validation steps for market re-entry after worldwide sales for 5 years. Drug-X maximizes the efficiency and outcomes of livestock assisted reproductive technologies (ART) such as in-vivo and in-vitro embryo transfer (ET). This veterinary-use-only drug is a “must-have” component for the global livestock embryo transfer industry.

Series A raised $1.2M from 30 angels

Deal Highlights:
a) Investor's total cash invested after Series B = $2,630,000
b) Investor's Equity = 45.1 % (5100 units issued, of which 2300 units are investor owned)
c) $1143 average price paid per unit issued ($1000/unit Series A; $1300/unit Series B)
d) Anticipated ROI based on $83M acquisition price would be 13X (1300% ROI)

Non-confidential Exec Summary upon request. [email protected]